Stock SNPX SYNAPTOGENIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Synaptogenix, Inc.

Equities

SNPX

US87167T3005

Delayed Nasdaq
Other stock markets
 21:30:01 09/05/2024 BST 		5-day change 1st Jan Change
4.71 USD +1.29% Intraday chart for Synaptogenix, Inc. -1.05% -30.71%
04-09 Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd. CI
04-03 Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery
PR
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
PR
Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics
PR
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing
PR
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders
PR
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's
PR
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by the Technion, Israel Institute of Technology
AQ
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology
PR
Niemann-Pick-Disease Pipeline, FDA Approvals, Clinical Trials, and Emerging Drugs 2023 (Updated)
AQ
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease
PR
Synaptogenix : Certificate of Incorporation/Bylaws - Form 8-K
PU
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study
PR
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis
AQ
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis
PR
Stocks Set to Soar on News (EPAZ, BOPO, MBRX, SNPX)
AQ
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience
PR
SYNAPTOGENIX, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
SYNAPTOGENIX, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
SYNAPTOGENIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
Synaptogenix : Results of Operations and Financial Condition - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SNPX Stock
  4. News Synaptogenix, Inc.
  5. Press Releases